



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study

Citation for published version:

Wang, X, Li, J, Moullaali, TJ, Lee, K, Kim, BJ, Bae, H, Wang, A, Wang, Y, Wang, DZ, Wang, Y, Kumamoto, M, Toyoda, K, Koga, M, Sato, S, Yoshimura, S, Sui, Y, Xu, B, Xiao, Y, Lee, T, Liou, C, Lee, J, Peng, T, Huang, Y, Paliwal, PR, Sharma, M, Escabillas, C, Navarro, JC, Sun, M, Dong, Y, Dong, Q, Anderson, CS & Sharma, VK 2019, 'Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study', *International Journal of Stroke*, pp. 174749301985877. <https://doi.org/10.1177/1747493019858777>

Digital Object Identifier (DOI):

[10.1177/1747493019858777](https://doi.org/10.1177/1747493019858777)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

International Journal of Stroke

Publisher Rights Statement:

This is the authors' peer-reviewed manuscript as accepted for publication.


General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Low-dose versus standard-dose alteplase in acute ischaemic stroke in Asian stroke registries: an individual patient data pooling study

Journal:	<i>International Journal of Stroke</i>
Manuscript ID	IJS-12-18-6812.R1
Manuscript Type:	Review
Date Submitted by the Author:	27-Mar-2019

Complete List of Authors:	<p>Wang, Xia; The George Institute for Global Health , Neurological & Mental Health Division</p> <p>li, jINGWEI</p> <p>Moullaali, Tom; George Institute for Global Health, Vascular and metabolic; University of Edinburgh Division of Health Sciences, Centre for Clinical Brain Sciences</p> <p>Lee, Keon-Joo; Seoul National University Hospital, Neurology</p> <p>Kim, Beom Joon; Seoul National University Bundang Hospital, Neurology</p> <p>Bae, Hee-Joon</p> <p>Wang, Anxin; Beijing Tiantan Hospital, Capital Medical University, Department of Neurology</p> <p>Wang, Yilong</p> <p>Wang, David</p> <p>Wang, Yongjun ; Beijing Tiantan Hospital,</p> <p>Kumamoto, Masaya</p> <p>Toyoda, Kazunori; National Cerebral and Cardiovascular Center, Department of Cerebrovascular Medicine</p> <p>Koga, Masatoshi; National Cerebral and Cardiovascular Center, Division of Stroke Care Unit</p> <p>Sato, Shoichiro; National Cerebral and Cardiovascular Center, Department of Cerebrovascular Medicine</p> <p>Yoshimura, Sohei ; The George Institute for Global Health, Neurological & Mental Health Division; Kokuritsu Junkankibyō Kenkyū Center, Department of Cerebrovascular Medicine</p> <p>Sui, Yi</p> <p>Xu, Bin</p> <p>Xiao, Ying</p> <p>Lee, Tsong-Hai</p> <p>Liou, Chia-Wei; Chang Gung Memorial Hospital Kaohsiung Medical Center, Stroke Center and Department of Neurology</p> <p>Lee, Jiann-Der</p> <p>Peng, Tsung-I</p> <p>Huang, Yen-Chu; Chang-Gung Memorial Hospital, Neurology</p> <p>Paliwal, Prakash</p> <p>Sharma, Manasi</p> <p>Escabillas, Cyrus</p> <p>Navarro, Jose; University of Santo Tomas Hospital, Stroke Services</p> <p>Sun, Mu-Chien; Changhua Christian Hospital, Neurology</p> <p>Dong, Yi</p> <p>Dong, Qiang; Huashan Hospital, State Key of Laboratory of Neurobiology, Fudan University, Department of Neurology</p> <p>Anderson, Craig; University of New South Wales, The George Institute for Global Health, Faculty of Medicine; Peking University Health Sciences Centre, ; Royal Prince Alfred Hospital</p> <p>Sharma, Vijay; National University of Singapore,</p>
Keywords:	Acute stroke therapy, Asia, rtPA, Stroke, Thrombolysis, Ischaemic stroke

Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study

Xia Wang, PhD¹ Jingwei Li, PhD^{2,3} Tom J Moullaali, MD^{1,4} Keon-Joo Lee,⁵ Beom Joon Kim,⁵ Hee-Joon Bae,⁵ Anxin Wang, PhD⁶ Yilong Wang, MD⁶ David Z. Wang, MD⁷ Yongjun Wang, MD⁶ Masaya Kumamoto, MD⁸ Kazunori Toyoda, MD⁸ Masatoshi Koga, MD⁸ Shoichiro Sato, MD⁸ Sohei Yoshimura, MD⁸ Yi Sui, MD⁹ Bing Xu, MD⁹ Ying Xiao, MD⁹ Tsong-Hai Lee, MD¹⁰ Chia-Wei Liou, MD¹¹ Jiann-Der Lee, MD¹², Tsung-I Peng, MD¹³, Yen-Chu Huang, MD¹², Prakash R Paliwal, MD,¹⁴ Manasi Sharma, MD,¹⁴ Cyrus Escabillas, MD¹⁵ Jose C. Navarro, MD¹⁵ Mu-Chien Sun, MD¹⁶, Yi Dong, MD¹⁷, Qiang Dong, MD¹⁷, Craig S Anderson, MD, PhD^{1,18}, Vijay K. Sharma, MD^{14,19}

¹The George Institute for Global Health, Faculty of Medicine, University of New South Wales, NSW, Australia

²Department of Cardiology, People's Liberation Army General Hospital, Beijing, China

³Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, China

⁴Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

⁵The Department of Neurology and Cerebrovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea

⁶Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁷College of Medicine, University of Illinois, Peoria, USA

⁸Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan

⁹Shenyang First People's Hospital, Shenyang Medical College Affiliated Shenyang Brain Hospital, Shenyang Brain Institute, Shenyang Clinical Research Center for Neurological Disorders

¹⁰Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and College of Medicine, Chang Gung University, Taoyuan, Taiwan

¹¹Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

¹²Department of Neurology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

¹³Department of Neurology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

¹⁴Division of Neurology, National University Hospital, Singapore

¹⁵Stroke Services, Department of Neurology, Jose R. Reyes Memorial Medical Center, Manila, Philippines

¹⁶Department of Neurology, Changhua Christian Hospital, Taiwan

¹⁷Department of Neurology, Huashan Hospital affiliated to Fudan University, Shanghai, China

¹⁸The George Institute China at Peking University Health Science Center, Beijing, PR China

¹⁹Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Corresponding Author

Professor Craig S Anderson

The George Institute for Global Health

PO Box M201, Missenden Road, NSW 2050, AUSTRALIA

T: +61-2-9993-4500; F: +61-2-9993-4502

Email: canderson@georgeinstitute.org.au

Professor Yongjun Wang

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantanxili, Dongcheng District, Beijing, China 100050.

E-mail yongjunwang1962@gmail.com

Statistical analysis:

Dr Xia Wang

The George Institute for Global Health

PO Box M201, Missenden Road, NSW 2050, AUSTRALIA

Email: xwang@georgeinstitute.org.au

Disclosures:

X Wang reports receiving research grant from the George Institute for Global Health. T.J. Moullaali reports grants from British Heart Foundation. C.S. Anderson reports receiving fees for Advisory Panels of Astra Zeneca and Medtronic, speaking at seminars for Takeda China and Boehringer Ingelheim, and a research grant from Takeda China. All other authors report no disclosures.

Word counts: abstract 231; body 1916

Abstract

Objective: To investigate the comparative efficacy and safety of the low-dose versus standard-dose alteplase using real-world acute stroke registry data from Asian countries.

Methods: Individual participant data were obtained from 9 acute stroke registries from China, Japan, Philippines, Singapore, South Korea and Taiwan between 2005 and 2018. Inverse probability of treatment weight was used to remove baseline imbalances between those receiving low-dose vs standard-dose alteplase. The primary outcome was death or disability defined by modified Rankin Scale (mRS) scores of 2-6 at 90 days. Secondary outcomes were symptomatic intracerebral hemorrhage (sICH) and death. Generalized linear mixed models with the individual registry as a random intercept were performed to determine associations of treatment with low-dose alteplase and outcomes.

Results: Of the 6250 patients (mean age 66 years, 36% women) included in these analyses, 1610 (24%) were treated with low-dose iv alteplase. Clinical outcomes for low-dose alteplase were not significantly different to those for standard-dose alteplase, adjusted odds ratios for death or disability: 1.00 (0.85-1.19) and sICH 0.87 (0.63-1.19), except for lower death with borderline significance, 0.77 (0.59-1.01).

Conclusions: The present analyses of real-world Asian acute stroke registry data suggest that low-dose iv alteplase has overall comparable efficacy for functional recovery and greater potential safety in terms of reduced mortality, to standard-dose alteplase for the treatment of acute ischemic stroke.

Key words- acute ischemic stroke; thrombolysis; alteplase dose; symptomatic intracranial hemorrhage; individual patient analysis; Asian

Introduction

Recombinant tissue plasminogen activator (rtPA/alteplase) is the established treatment for acute ischemic stroke (AIS). Most guidelines^{1,2} recommend an intravenous (iv) dose of 0.9 mg/kg of alteplase (10% as a bolus and the remaining as an infusion over 1-hour; maximum dose 90mg) to eligible patients with AIS, presenting within 3 or 4.5 hours of symptom-onset, based on the National Institute of Neurological Disorders and Stroke (NINDS)³ and the European Cooperative Acute Stroke Study (ECASS) trials,⁴⁻⁶ respectively. However, a dose of 0.6 mg/kg (10% as a bolus and the remaining as an infusion over 1 hour; maximum dose 60mg) is the approved dose of alteplase in Japan⁷, where non-randomized studies⁸⁻¹¹ have suggested comparable clinical outcomes and reduced risk of symptomatic intracerebral hemorrhage (sICH) compared to the standard-dose.^{8,9} In other Asian countries, low-dose alteplase is used widely, largely due to the reduced cost and anticipated lower rates of sICH.^{12, 13}

The ENhanced Control of Hypertension And Thrombolysis strokeE stuDY (ENCHANTED)¹³⁻¹⁵ has been the only randomized comparison of low- versus standard-dose iv alteplase in AIS patients who fulfilled standard eligibility criteria for this treatment. The study demonstrated that low-dose alteplase did not meet the stringent non-inferiority criteria compared to standard-dose alteplase with respect to the conventional binary clinical endpoint of death and disability, defined by scores of 2-6 on the modified Rankin scale (mRS) at 90 days. However, low-dose alteplase was non-inferior with respect to an ordinal analysis of this endpoint, and there were significantly fewer cases of sICH across all standard criteria in the low-dose alteplase group. The ENCHANTED results have stimulated debate about the widespread use of low-dose alteplase in Asian medical practice.

Systematic reviews^{16, 17} comparing low- and standard-dose alteplase have shown little difference in clinical outcomes, possibly due to individual studies being under-powered.

Hence, we initiated an international collaborative, individual patient data (IPD) pooling project, to compare low- and standard-dose alteplase, with the aim of providing reliable evidence about the optimal dose of iv alteplase for Asian AIS patients.

METHODS

This study was based on IPD and adhered to the PRISMA-IPD (Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data).¹⁸ All participating studies were approved by their local ethics committees. Data were obtained from 9 stroke registries from 6 Asian countries (China, Japan, Philippines, Singapore, South Korea and Taiwan), 6 of which were identified by a systematic search, representing 50% of the 12 potentially eligible studies with sample size over 100;¹⁹ 3 were unpublished. We requested de-identified IPD on patient characteristics, the dose of alteplase and outcomes from the study investigators. The reasons for excluding 6 studies were ethical approval not being granted (4) and refusal to participate (2) (Supplementary table 1).

We collected information on factors that might explain the differences in the association between alteplase-dose treatment and outcomes including: (i) alteplase treatment (time from onset to treatment and dosage); (ii) demographics (age, sex, body weight, country of recruitment); (iii) medical history (hypertension, previous stroke, coronary artery disease, atrial fibrillation, diabetes, hypercholesterolemia and smoking); (iv) medication history (antihypertensive medication, lipid-lowering medication, antidiabetic medication, warfarin use, aspirin or other antiplatelet use); (v) hemodynamic parameters (systolic/diastolic blood pressure, heart rate); and (vi) stroke severity (the National Institute of Health Stroke Scale [NIHSS]) and stroke etiology according to the Trial of Org 10172 in acute stroke treatment (TOAST) classification²⁰.

Functional outcome was measured by mRS at 3 months. The definition of sICH varied among the studies: 3 studies defined it as per the NINDS trial³, 5 studies defined it as radiological evidence of ICH associated with neurological deterioration (4 used a corresponding 4-points increase on the NIHSS; 1 study used a 2-point increase), and 1 study defined it as per the ECASS II⁵ trial (any ICH with neurological deterioration [>4 points on the NIHSS] from baseline or death within 24 to 36 hours) (Supplementary table 2).

Data not provided in the article because of space limitations may be shared (anonymized) at the request of any qualified investigator for purposes of replicating procedures and results.

Statistical analysis

Initial internal analyses were performed to compare baseline and outcome data from each study with their published results to ensure that data were complete and transferred without error. Since most of the individual study results have already been published, results from analysis of individual studies will not be identifiable in this publication. We, therefore, used the 1-stage method of analysis proposed for IPD meta-analyses.

The characteristics of the low-dose alteplase group were expected to substantially differ from those of the standard-dose group. To generate a comparable data set, we calculated a propensity score to estimate the individual probability of a patient receiving low-dose alteplase. Six variables were used as covariates to calculate propensity scores (sex, age, baseline systolic blood pressure [SBP], baseline NIHSS, premorbid mRS, time from onset to treatment, and presence of vascular risk factors [prior transient ischemic stroke, stroke, hypertension, coronary artery disease, atrial fibrillation, diabetes or hypercholesterolemia]). The inverse probability of treatment weighting (IPTW) was used as the primary strategy to adjust for baseline imbalances.²¹ Data balancing was examined using an absolute standardized difference in covariate means.²² The distributions of baseline covariates were

fairly well balanced by applying propensity scores; the absolute standardized differences after IPTW were within an acceptable margin of 0.1 (supplementary figure 1). Stabilized weights²³ were used to reduce variance of the estimated effect of low-dose alteplase, and were incorporated into generalized linear mixed models with the individual registry as a random intercept to determine associations of treatment with low/standard-dose alteplase and outcomes.

For all analyses involving the primary outcome of functional recovery (ordinal scores on the mRS), we checked the proportional odds assumption was not violated; where this was violated, we present functional outcome according to binary mRS scores. Subgroup analyses by key demographic variables (sex; age <65 vs. ≥65 years), clinical severity (defined by NIHSS scores <10 vs. ≥10 points), treatment (time from onset to treatment <3 vs. ≥3 hours), TOAST classification (large-artery atherosclerosis, small-vessel, cardioembolism, and other etiology) and premorbid mRS (0-1 vs. 2-5) were undertaken to test the consistency of any association. We assessed the heterogeneity of association in subgroups by adding an interaction term in the models. Data are presented as odds ratios (OR) and 95% confidence intervals (CI). A two sided $P < 0.05$ was set as the level for statistical significance. All statistical analyses were performed using SAS version 9.3 (SAS institute, Cary, NC, USA).

Results

There were 6852 patients from 8 studies, 6250 of which were treated either by low-dose alteplase (0.55-0.65 mg/kg, 23.4%) or standard-dose alteplase (0.85-0.95 mg/kg, 66.6%). Data for sICH were available in all patients, mRS data in 4055, and sICH data in 6250 patients. The mean age of the patients was 66 years, 37% were female, and the median NIHSS was 10 (IQR 6-16). Table 1 shows the baseline characteristics of patients according to alteplase dosage: those in the low-dose group were significantly older and more neurologically impaired, and a higher proportion were female, hypertensive, and with co-

morbidity. Additionally, strokes due to large-artery atherosclerosis were more likely to be treated with standard-dose alteplase, while strokes due to cardioembolism were more likely to be treated with low-dose alteplase.

The distribution of mRS scores at 3 months was shown in figure 1. Compared to standard-dose alteplase, treatment with low-dose alteplase was not associated with death and disability (mRS 2-6) at 3 months (OR 1.00, CI 0.85-1.19) or sICH (OR 0.87, CI 0.63-1.19) (Figure 2). However, treatment with low-dose alteplase was associated with lower risk of 3-month mortality with borderline significance (OR 0.77, CI 0.59-1.01).

Figure 3 shows that associations were consistent across the key subgroups by age, sex, stroke severity, time from onset to treatment, and stroke subtype. Although, significant heterogeneity was evident for dichotomised pre-morbid mRS (0-1 vs. 2-5), the current study is under-powered to explore the association for the subgroup of pre-morbid mRS 2-5.

DISCUSSION

This IPD meta-analysis aimed to provide reliable evidence about the efficacy and safety of low-dose alteplase in real world Asian populations, adjusted for important confounders. Our analyses of pooled data from 9 real-world acute stroke registries from Asian countries show that low-dose alteplase treatment of AIS has comparable overall efficacy and potentially improved safety compared with standard-dose alteplase when used to treat AIS within 4.5 hours of onset.

We confirm findings from previous comprehensive systematic reviews that show low- and standard-dose alteplase have equivalent outcomes for the treatment of AIS.^{12, 19} In the present study, 63% of patients who were treated with low-dose alteplase had the outcome of death or disability (mRS 2-6), which is similar to the single-arm nonrandomized studies first and second Japan Alteplase Clinical Trial (J-ACT 1 and 2), and the Japan Post-marketing

Alteplase Registration Study (JMARS). Additionally, 55% of patients treated with standard-dose alteplase had the outcome of death or disability, which is comparable to data from the multinational Safe Implementation of Thrombolysis in Stroke–Non-European Union World study,²⁴ NINDS trial,³ and the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST).²⁵ These similarities support the reliability of our large dataset of pooled real-world IPD.

In regard to functional outcome at 90 days, we found that for those treated with low-dose alteplase, a smaller proportion of deaths was accompanied by an increase in moderate to severe disability amongst survivors – a finding that is consistent with that of the ENCHANTED trial. This finding occurred despite differences in patient characteristics at baseline; patients enrolled in ENCHANTED were younger, had milder deficits, were treated with alteplase at a longer time from the onset of symptoms, and were less likely to have atrial fibrillation or major arterial occlusion. These factors may be considered barriers to implementation of the ENCHANTED findings directly into clinical practice, however our real-world data provide support for the generalizability of these trial results.

A notable point of difference relates to alteplase dose and sICH risk; the ENCHANTED trial showed that low-dose alteplase significantly reduced the risk of sICH, however our analyses showed no such association. This discordance could be explained by differences between the definitions used to identify sICH in a clinical trial and across real-world clinical practice in several different healthcare systems; it may also be explained by inadequate adjustment for confounders. For example, we did not have information on prior antiplatelet or anticoagulant use, both of which are important prognostic factors in thrombolysis-associated ICH. Another limitation of the present study is data availability bias arising from our inability to acquire IPD from 4 large registries in Japan and Taiwan (8840 patients) due to ethical approval issues. In addition, there is significant difference in time from onset to treatment and

countries contributing standard and low-dose alteplase patients which may have affected our overall results. However higher age, higher NIHSS are points against for low-dose alteplase, which may have nullified effects though we have conducted propensity score matching analysis.

Prior to this work, observational studies from Asia reported conflicting findings. For instance, low-dose alteplase was found to be equivalent to standard-dose in a large observational registry from South Korea.²⁶ Conversely, the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke registry in China showed that standard-dose alteplase produced favorable outcomes without increasing the risk of sICH.²⁷ Therefore, our analyses of pooled IPD, which include the aforementioned studies, provide clarity in producing a comprehensive summary of the evidence, and greater power to detect meaningful associations between alteplase dose and outcome, adjusted for important confounders.

In summary, this international collaborative project, curated and analyzed IPD from a wide variety of Asian stroke registry studies, reports that low- and standard-dose alteplase have equivalent outcomes in AIS. This finding needs to be confirmed in a randomised clinical trial including patients undergoing mechanical thrombectomy as well.

References

1. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2016;47:581-641.
2. Royal College of Physicians. Stroke guidelines. <https://www.rcplondon.ac.uk/guidelines-policy/stroke-guidelines> (accessed November 24, 2016).
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *The New England Journal of Medicine* 1995;333:1581-1587.
4. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA* 1995;274:1017-1025.
5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet* 1998;352:1245-1251.
6. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *The New England Journal of Medicine* 2008;359:1317-1329.
7. Minematsu K, Toyoda K, Hirano T, et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. *Journal of stroke and cerebrovascular diseases* 2013;22:571-600.
8. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). *Stroke* 2006;37:1810-1815.
9. Mori E, Minematsu K, Nakagawara J, et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). *Stroke* 2010;41:461-465.
10. Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). *Stroke* 2010;41:1984-1989.
11. Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. *Stroke* 2009;40:3591-3595.
12. Sharma VK, Ng KW, Venketasubramanian N, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. *Int J Stroke* 2011;6:523-530.
13. Huang Y, Sharma VK, Robinson T, et al. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis stroke stuDy (ENCHANTED) trial: An international multicenter 2 x 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischemic stroke eligible for thrombolysis treatment. *Int J Stroke* 2015;10:778-788.
14. Anderson CS, Robinson T, Lindley RI, et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. *The New England Journal of Medicine* 2016;374:2313-2323.

15. Anderson CS, Woodward M, Arima H, et al. Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis stroke stuDY (ENCHANTED). *Int J Stroke* 2015;10:1313-1315.
16. Liu MD, Ning WD, Wang RC, et al. Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis. *Medicine* 2015;94:e2412.
17. Sharma VK, Ng KWP, Venketasubramanian N, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. *Int J Stroke* 2011;6:523-530.
18. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* 2015;313:1657-1665.
19. Wang X, You S, Sato S, et al. Current status of intravenous tissue plasminogen activator dosage for acute ischemic stroke: an updated systematic review. *Stroke Vasc Neurol* 2018;3:28-33.
20. Adams HP, Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35-41.
21. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology* 2000;11:550-560.
22. Haviland A, Nagin DS, Rosenbaum PR. Combining propensity score matching and group-based trajectory analysis in an observational study. *Psychol Methods* 2007;12:247-267.
23. Rheta E, Lanehart PRdG, Eun Sook Kim, Aarti P. Bellara, Jeffrey D., Kromrey aRSL. Propensity score analysis and assessment of propensity score approaches using SAS procedures [online]. Available at: <http://support.sas.com/resources/papers/proceedings12/314-2012.pdf>.
24. Rha JH, Shrivastava VP, Wang Y, et al. Thrombolysis for acute ischemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). *International Journal of Stroke* 2014;9 Suppl A100:93-101.
25. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. *Lancet* 2007;369:275-282.
26. Kim BJ, Han MK, Park TH, et al. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study. *Stroke* 2015;46:2541-2548.
27. Liao X, Wang Y, Pan Y, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. *Stroke* 2014;45:2354-2358.
28. Chao AC, Hsu HY, Chung CP, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. *Stroke* 2010;41:885-890.
29. Nguyen TH, Truong AL, Ngo MB, et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. *Eur J Neurol* 2010;17:1188-1192.
30. Zhou XY, Wang SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. *Journal of Clinical Neuroscience* 2010;17:988-992.
31. Chen CH, Hsieh CY, Lai TB, Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: Low dose may have similar safety and efficacy as standard dose. *Journal of Thrombosis and Haemostasis* 2012;10:1270-1275.

32. Chao AC, Liu CK, Chen CH, et al. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. *Stroke* 2014;45:2359-2365.

For Review Only

Figure legends

Figure 1: mRS distribution by low-dose versus standard-dose alteplase

Figure 2: Association between low-dose and standard-dose alteplase and clinical outcomes

Model a: propensity score was derived from the model with sex, age, baseline NIHSS, time from onset to treatment, and risk factor (prior TIA, stroke, hypertension, coronary artery disease, AF, diabetes, or hypercholesterolemia]

Model b: propensity score was derived from the model with sex, age, baseline NIHSS score, premorbid modified Rankin Scale(mRS), time from onset to treatment, and risk factor (prior TIA, stroke, hypertension, coronary artery disease, AF, diabetes, or hypercholesterolemia]

Figure 3 subgroup analysis

Table 1. Baseline characteristics

	Standard-dose alteplase (0.9 mg/kg) (n=4640)	Low-dose alteplase (0.6 mg/kg) (n=1610)	P value
Age, mean (SD)	65.1(12.0)	68.4(12.9)	<0.0001
Female	1640/4598(35.7)	604/1548(39.0)	0.018
Time from stroke onset to treatment, median(IQR)	2.52(1.83-3.08)	2.30(1.75-2.83)	<0.0001
Country			<0.0001
China	2877/4640(62.0)	347/1610(21.6)	
Korea	1076/4640(23.2)	450/1610(28.0)	
Japan	0(0.00)	600/1610(37.3)	
Taiwan	368/4640(7.9)	22/1610(1.4)	
Singapore	224/4640(4.8)	135/1610(8.4)	
Philippines	95/4640(2.1)	56/1610(3.5)	
NIHSS, median(IQR)	9(5-15)	11(6-18)	<0.0001
SBP	148.6(24.9)	151.1(23.6)	0.0002
DBP	86.2(14.9)	84.3(16.0)	<0.0001
Pre-morbid mRS			<0.0001
0-1	2610/4117(63.4)	1100/1413(77.9)	
2-5	1507/4117(36.6)	313/1413(22.2)	
Smoking	1662/4512(36.8)	368/1007(36.5)	0.863
Prior stroke	657/3545(18.5)	237/1149(20.6)	0.116
Prior coronary artery disease	104/2281(4.6)	160/944(17.0)	<0.0001
Prior atrial fibrillation	1097/4640(23.6)	606/1600(37.9)	<0.0001
Prior hypertension	2961/4640(63.8)	1068/1606(66.5)	0.053
Prior dislipidemia	853/4638(18.4)	438/1603(27.3)	<0.0001
Prior diabetes mellitus	1046/4640(22.5)	383/1609(23.8)	0.300
TOAST classification			<0.0001
Large-artery atherosclerosis	854/2287(37.3)	369/1475(25.0)	
Small-vessel occlusion	243/2287(10.6)	143/1475(9.7)	
Cardioembolism	678/2287(29.7)	694/1475(47.1)	
Others	512/2287(22.4)	269/1475(18.2)	

SD: standard deviation; IQR: interquartile range; mRS: modified Rankin Scale; TOAST: Aetiological Trial of Org 10172 in acute stroke treatment (TOAST) classification




Figure 1





Figure 2






Figure 3

